Previous 10 | Next 10 |
Exelixis ( NASDAQ: EXEL ) is accusing MSN Pharmacueticals of patent infringement over its Abbreviated New Drug Application to market a generic of Cabometyx (cabozantinib). The lawsuit was filed Monday in a Delaware federal court. Exelixis is assert infringement of ...
As of June 30, 2022, AAII’s Oberweis Octagon screening model has an annual gain since inception (1998) of 11.4%. The AAII Oberweis Octagon strategy seeks rapidly growing small- to mid-size companies trading at attractive prices. The Oberweis Octagon screen seeks to identify...
Exelixis ( NASDAQ: EXEL ) on Monday said its phase 3 trial evaluating its cabozantinib medicine in combination with two other cancer drugs for the treatment of kidney cancer met its main goal. The late-stage trial, called COSMIC-313, is investigating EXEL's cabozantini...
– Exelixis intends to discuss the results with the U.S. FDA to determine next steps toward a potential regulatory submission – – Trial to continue until the next analysis of the secondary endpoint of overall survival – Exelixis, ...
Exelixis ( NASDAQ: EXEL ) signed a licensing agreement with Poland-based Ryvu Therapeutics to develop novel targeted cancer therapies. Under the terms of the agreement, Exelixis will pay Ryvu $3M upfront in exchange for certain rights to Ryvu's STING agonist small...
– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology, which has best-in-class potential – Exelixi...
-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand begi...
The stock market might not look so attractive right now, with the S&P 500 down 18% so far this year. But even good businesses with strong fundamentals experience ups and downs. It doesn't mean these stocks should be abandoned. History tells us a distressed market creates investment ...
BMO Capital Markets has initiated the coverage of oncology-focused biotech Exelixis (NASDAQ:EXEL) with an Outperform recommendation arguing that the company shares are trading below a worst-case scenario implied for a potential entry of generics. The price target of $28 per share implies a pr...
Exelixis (NASDAQ:EXEL) said it began a phase 3 trial of XL092 in combination with Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) Tecentriq (atezolizumab) versus Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) Stivarga (regorafenib) in patients with metastatic colorectal cancer which is not microsatellite insta...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...